Short-term and rapid effects of lysophosphatidic acid on human adipose cell lipolytic and glucose uptake activities

Christian Carpéné; Jean Galitzky; Jean Sébastien Saulnier-Blache; Christian Carpéné; Jean Galitzky; Jean Sébastien Saulnier-Blache

doi:10.3934/molsci.2016.2.222

AIMS Molecular Science

2016, Volume 3, Issue 2: 222-237. doi: 10.3934/molsci.2016.2.222

Previous Article Next Article

Research article

Short-term and rapid effects of lysophosphatidic acid on human adipose cell lipolytic and glucose uptake activities

1.
Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale (INSERM U1048), I2MC, 31432 Toulouse Cedex 4, France
2.
Université Paul Sabatier, I2MC-UPS, CHU Rangueil, Toulouse, France

Received: 22 February 2016 Accepted: 12 May 2016 Published: 16 May 2016

Lysophosphatidic acid (LPA) is a bioactive phospholipid that activates cell proliferation, differentiation and migration via the activation of its membrane-bound receptors (LPAR 1 to 6) expressed in various tissues and organs. Adipose tissue produces LPA, which, in turn, increases preadipocyte proliferation, mainly through the stimulation of LPA1R. However, while LPA plasma levels increase with obesity, only few studies have investigated the acute autocrine properties of LPA on mature adipocytes. We therefore assessed the lipolytic and antilipolytic effects of LPA on human adipocytes. Here, we show that, in human subcutaneous adipocytes, LPA (0.1–10 µM) did not mimic insulin effects in human adipocytes, i.e. lipolysis inhibition and glucose uptake activation. By contrast, supramicromolar doses of the phospholipid slightly activated lipolysis, and the effect of 100 µM LPA was additive to the β-adrenergic stimulation of lipolysis by isoprenaline. Moreover, LPA did not alter the activity of primary amine oxidase, an enzyme highly expressed in human adipose cells. Our observations indicate that, although rapid and direct, LPA impact on triglyceride storage in mature adipocytes is less pronounced than its ability to stimulate proliferation in preadipocytes.
- adipocytes,
- autotaxin,
- 2-deoxyglucose,
- amine oxidases,
- vanadium,
- glycerol
Citation: Christian Carpéné, Jean Galitzky, Jean Sébastien Saulnier-Blache. Short-term and rapid effects of lysophosphatidic acid on human adipose cell lipolytic and glucose uptake activities[J]. AIMS Molecular Science, 2016, 3(2): 222-237. doi: 10.3934/molsci.2016.2.222

Related Papers:

Abstract

Lysophosphatidic acid (LPA) is a bioactive phospholipid that activates cell proliferation, differentiation and migration via the activation of its membrane-bound receptors (LPAR 1 to 6) expressed in various tissues and organs. Adipose tissue produces LPA, which, in turn, increases preadipocyte proliferation, mainly through the stimulation of LPA1R. However, while LPA plasma levels increase with obesity, only few studies have investigated the acute autocrine properties of LPA on mature adipocytes. We therefore assessed the lipolytic and antilipolytic effects of LPA on human adipocytes. Here, we show that, in human subcutaneous adipocytes, LPA (0.1–10 µM) did not mimic insulin effects in human adipocytes, i.e. lipolysis inhibition and glucose uptake activation. By contrast, supramicromolar doses of the phospholipid slightly activated lipolysis, and the effect of 100 µM LPA was additive to the β-adrenergic stimulation of lipolysis by isoprenaline. Moreover, LPA did not alter the activity of primary amine oxidase, an enzyme highly expressed in human adipose cells. Our observations indicate that, although rapid and direct, LPA impact on triglyceride storage in mature adipocytes is less pronounced than its ability to stimulate proliferation in preadipocytes.

References

[1]	Noguchi K, Herr D, Mutoh T, et al. (2009) Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 9: 15-23. doi: 10.1016/j.coph.2008.11.010
[2]	Yung YC, Stoddard NC, Chun J (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. J Lipid Res 55: 1192-1214. doi: 10.1194/jlr.R046458
[3]	van Meeteren LA, Ruurs P, Stortelers C, et al. (2006) Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 26: 5015-5022. doi: 10.1128/MCB.02419-05
[4]	Tanaka M, Okudaira S, Kishi Y, et al. (2006) Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem 281: 25822-25830. doi: 10.1074/jbc.M605142200
[5]	Gesta S, Simon MF, Rey A, et al. (2002) Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis. J Lipid Res 43: 904-910.
[6]	Ferry G, Tellier E, Try A, et al. (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278: 18162-18169.
[7]	Boucher J, Quilliot D, Pradere JP, et al. (2005) Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 48: 569-577. doi: 10.1007/s00125-004-1660-8
[8]	Rancoule C, Dusaulcy R, Tréguer K, et al. (2012) Depot-specific regulation of autotaxin with obesity in human adipose tissue. J Physiol Biochem 68: 635-644. doi: 10.1007/s13105-012-0181-z
[9]	Pagés G, Girard A, Jeanneton O, et al. (2000) LPA as a paracrine mediator of adipocyte growth and function. Ann N Y Acad Sci 905: 159-164.
[10]	Simon MF, Daviaud D, Pradere JP, et al. (2005) Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2. J Biol Chem 280: 14656-14662. doi: 10.1074/jbc.M412585200
[11]	Dusaulcy R, Daviaud D, Pradere JP, et al. (2009) Altered food consumption in mice lacking lysophosphatidic acid receptor-1. J Physiol Biochem 65: 345-350. doi: 10.1007/BF03185929
[12]	Dusaulcy R, Rancoule C, Grès S, et al. (2011) Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res 52: 1247-1255. doi: 10.1194/jlr.M014985
[13]	Rancoule C, Attané C, Grès S, et al. (2013) Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice. Diabetologia 56: 1394-1402. doi: 10.1007/s00125-013-2891-3
[14]	Rancoule C, Viaud M, Grès S, et al. (2014) Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: in vivo and in vitro evidence. Biochim Biophys Acta 1841: 88-96. doi: 10.1016/j.bbalip.2013.10.003
[15]	Dalfó E, Hernandez M, Lizcano JM, et al. (2003) Activation of human lung semicarbazide sensitive amine oxidase by a low molecular weight component present in human plasma. Biochim Biophys Acta 1638: 278-286. doi: 10.1016/S0925-4439(03)00094-2
[16]	Bour S, Daviaud D, Grès S, et al. (2007) Adipogenesis-related increase of semicarbazide-sensitive amine oxidase and monoamine oxidase in human adipocytes. Biochimie 89: 916-925. doi: 10.1016/j.biochi.2007.02.013
[17]	Iglesias-Osma MC, Garcia-Barrado MJ, Visentin V, et al. (2004) Benzylamine exhibits insulin-like effects on glucose disposal, glucose transport, and fat cell lipolysis in rabbits and diabetic mice. J Pharmacol Exp Ther 309: 1020-1028. doi: 10.1124/jpet.103.063636
[18]	Mercader J, Wanecq E, Chen J, et al. (2011) Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in Citrus aurantium. J Physiol Biochem 67: 443-452. doi: 10.1007/s13105-011-0078-2
[19]	Visentin V, Morin N, Fontana E, et al. (2001) Dual action of octopamine on glucose transport into adipocytes: inhibition via beta3-adrenoceptor activation and stimulation via oxidation by amine oxidases. J Pharmacol Exp Ther 299: 96-104.
[20]	Iffiu-Soltesz Z, Prévot D, Carpéné C (2009) Influence of prolonged fasting on monoamine oxidase and semicarbazide-sensitive amine oxidase activities in rat white adipose tissue. J Physiol Biochem 65: 11-23. doi: 10.1007/BF03165965
[21]	Carpéné C, Chalaux E, Lizarbe M, et al. (1993) Beta 3-adrenergic receptors are responsible for the adrenergic inhibition of insulin-stimulated glucose transport in rat adipocytes. Biochem J 296: 99-105. doi: 10.1042/bj2960099
[22]	Iglesias-Osma MC, Bour S, Garcia-Barrado MJ, et al. (2005) Methylamine but not mafenide mimics insulin-like activity of the semicarbazide-sensitive amine oxidase-substrate benzylamine on glucose tolerance and on human adipocyte metabolism. Pharmacol Res 52: 475-484. doi: 10.1016/j.phrs.2005.07.008
[23]	Carpéné C, Bousquet-Melou A, Galitzky J, et al. (1998) Lipolytic effects of beta 1-, beta 2-, and beta 3-adrenergic agonists in white adipose tissue of mammals. Ann N Y Acad Sci 839: 186-189. doi: 10.1111/j.1749-6632.1998.tb10756.x
[24]	Castan I, Valet P, Quideau N, et al. (1994) Antilipolytic effects of alpha 2-adrenergic agonists, neuropeptide Y, adenosine, and PGE1 in mammal adipocytes. Am J Physiol 266: R1141-1147.
[25]	Sekharam M, Cunnick JM, Wu J (2000) Involvement of lipoxygenase in lysophosphatidic acid-stimulated hydrogen peroxide release in human HaCaT keratinocytes. Biochem J 346: 751-758. doi: 10.1042/bj3460751
[26]	Pizzinat N, Marti L, Remaury A, et al. (1999) High expression of monoamine oxidases in human white adipose tissue: evidence for their involvement in noradrenaline clearance. Biochem Pharmacol 58: 1735-1742. doi: 10.1016/S0006-2952(99)00270-1
[27]	Schimmel RJ, Honeyman TW, McMahon KK, et al. (1980) Inhibition of cyclic AMP accumulation in hamster adipocytes with phosphatidic acid: differences and similarities with alpha adrenergic effects. J Cyclic Nucleotide Res 6: 437-449.
[28]	Lafontan M, Bousquet-Melou A, Galitzky J, et al. (1995) Adrenergic receptors and fat cells: differential recruitment by physiological amines and homologous regulation. Obes Res 3 Suppl 4: 507s-514s.
[29]	Carpéné C, Schaak S, Guilbeau-Frugier C, et al. (2016) High intake of dietary tyramine does not deteriorate glucose handling and does not cause adverse cardiovascular effects in mice. J Physiol Biochem in press.
[30]	Liu YB, Kharode Y, Bodine PV, et al. (2010) LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem 109: 794-800.
[31]	Jun DJ, Lee JH, Choi BH, et al. (2006) Sphingosine-1-phosphate modulates both lipolysis and leptin production in differentiated rat white adipocytes. Endocrinology 147: 5835-5844. doi: 10.1210/en.2006-0579
[32]	Hirakawa M, Karashima Y, Watanabe M, et al. (2007) Protein kinase A inhibits lysophosphatidic acid-induced migration of airway smooth muscle cells. J Pharmacol Exp Ther 321: 1102-1108. doi: 10.1124/jpet.106.118042
[33]	Chang CL, Lin ME, Hsu HY, et al. (2008) Lysophosphatidic acid-induced interleukin-1 beta expression is mediated through Gi/Rho and the generation of reactive oxygen species in macrophages. J Biomed Sci 15: 357-363. doi: 10.1007/s11373-007-9223-x
[34]	Lee MJ, Jeon ES, Lee JS, et al. (2008) Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells. J Cell Biochem 104: 499-510. doi: 10.1002/jcb.21641
[35]	Carpéné C, Berlan M, Lafontan M (1983) Lack of functional antilipolytic alpha 2-adrenoceptor in rat fat cell:comparison with hamster adipocyte. Comp Biochem Physiol C 74: 41-45. doi: 10.1016/0742-8413(83)90145-7
[36]	Yea K, Kim J, Lim S, et al. (2008) Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake. J Mol Med (Berl) 86: 211-220. doi: 10.1007/s00109-007-0269-z
[37]	Thomson FJ, Moyes C, Scott PH, et al. (1996) Lysophosphatidic acid stimulates glucose transport in Xenopus oocytes via a phosphatidylinositol 3'-kinase with distinct properties. Biochem J 316: 161-166. doi: 10.1042/bj3160161
[38]	Keller JN, Steiner MR, Mattson MP, et al. (1996) Lysophosphatidic acid decreases glutamate and glucose uptake by astrocytes. J Neurochem 67: 2300-2305.
[39]	Rancoule C, Dusaulcy R, Tréguer K, et al. (2014) Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie 96: 140-143. doi: 10.1016/j.biochi.2013.04.010
[40]	McIntyre TM, Pontsler AV, Silva AR, et al. (2003) Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci U S A 100: 131-136. doi: 10.1073/pnas.0135855100
[41]	Iffiu-Soltesz Z, Mercader J, Daviaud D, et al. (2011) Increased primary amine oxidase expression and activity in white adipose tissue of obese and diabetic db-/- mice. J Neural Transm (Vienna) 118: 1071-1077. doi: 10.1007/s00702-011-0586-9
[42]	Rancoule C, Pradere JP, Gonzalez J, et al. (2011) Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs 20: 657-667. doi: 10.1517/13543784.2011.566864
[43]	Liu S, Umezu-Goto M, Murph M, ., et al. (2009) Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15: 539-550. doi: 10.1016/j.ccr.2009.03.027
[44]	Sibon I, Mercier N, Darret D, et al. (2008) Association between semicarbazide-sensitive amine oxidase, a regulator of the glucose transporter, and elastic lamellae thinning during experimental cerebral aneurysm development: laboratory investigation. J Neurosurg 108: 558-566. doi: 10.3171/JNS/2008/108/3/0558
[45]	Taylor LA, Arends J, Hodina AK, et al. (2007) Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis 6: 17. doi: 10.1186/1476-511X-6-17
[46]	Reeves VL, Trybula JS, Wills RC, et al. (2015) Serum Autotaxin/ENPP2 correlates with insulin resistance in older humans with obesity. Obesity (Silver Spring) 23: 2371-2376. doi: 10.1002/oby.21232
[47]	Visentin V, Prévot D, De Saint Front VD, et al. (2004) Alteration of amine oxidase activity in the adipose tissue of obese subjects. Obes Res 12: 547-555. doi: 10.1038/oby.2004.62

Reader Comments

your name:*

Email:*
© 2016 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)